COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Cash Flow Analysis including operating cash flow, investing cash flow, financing cash flow, free cash flow, cash flow from operations, cash flow from investing, cash flow from financing. Compare cash flow against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Cash Flow Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.

Operating Cash Flow per Share

46.24

Decreased from previous period

OCF/share of 46.24 while Medical - Pharmaceuticals median is zero. Walter Schloss would see if modest cash generation can build a stronger lead.

Free Cash Flow per Share

-7.93

Decreased from previous period

Negative FCF/share while Medical - Pharmaceuticals median is 0.00. Seth Klarman would question if the business is too capex-heavy.

Capex-to-Operating Cash Flow

117.15%

Increased from previous period

Capex/OCF ratio of 117.15% while the Medical - Pharmaceuticals median is zero. Walter Schloss would confirm if minimal reinvestment is enough for advantage.

Income Quality Ratio (OCF / Net Income)

0.80

Decreased from previous period

Ratio near Medical - Pharmaceuticals median of 0.87. Charlie Munger might see standard alignment across the industry.

Operating Cash Flow-to-Sales Ratio

3.27%

Decreased from previous period

OCF-to-sales ratio exceeding 1.5x Medical - Pharmaceuticals median of 1.34%. Joel Greenblatt would see a standout ability to convert sales to cash.

Select Chart Metric:

3349.T Cash Flow Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Operating Cash Flow per Share

46.24

Decreased from previous period

OCF/share of 46.24 while Medical - Pharmaceuticals median is zero. Walter Schloss would see if modest cash generation can build a stronger lead.

Free Cash Flow per Share

-7.93

Decreased from previous period

Negative FCF/share while Medical - Pharmaceuticals median is 0.00. Seth Klarman would question if the business is too capex-heavy.

Capex-to-Operating Cash Flow

117.15%

Increased from previous period

Capex/OCF ratio of 117.15% while the Medical - Pharmaceuticals median is zero. Walter Schloss would confirm if minimal reinvestment is enough for advantage.

Income Quality Ratio (OCF / Net Income)

0.80

Decreased from previous period

Ratio near Medical - Pharmaceuticals median of 0.87. Charlie Munger might see standard alignment across the industry.

Operating Cash Flow-to-Sales Ratio

3.27%

Decreased from previous period

OCF-to-sales ratio exceeding 1.5x Medical - Pharmaceuticals median of 1.34%. Joel Greenblatt would see a standout ability to convert sales to cash.

Select Chart Metric: